1CM
TVTX icon

1492 Capital Management’s Travere Therapeutics TVTX Stock Holding History

1492 Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,200
Closed -$207K – 131
2015
Q3 		$207K Buy
+10,200
New +$302K 0.15% 107

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1492 Capital Management's TVTX Position: Q4 2015 in Review

1492 Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2015, closing a stake of 10,200 shares — an estimated $207K sold.

1492 Capital Management first reported a position in TVTX in Q3 2015 and held it in 1 quarter. The position peaked at $207K in Q3 2015. 116 funds tracked by Wall St. Rank hold TVTX as of Q4 2015.

  • 1492 Capital Management reported no remaining Travere Therapeutics position as of Q4 2015 after selling out during the quarter.
  • 1492 Capital Management sold 10,200 Travere Therapeutics shares in Q4 2015, an estimated $207K.
  • 1492 Capital Management first reported a position in Travere Therapeutics in Q3 2015 and held it in 1 quarter.
  • 1492 Capital Management's Travere Therapeutics position peaked at $207K in Q3 2015.
  • 116 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2015.

Based on 1492 Capital Management's 13F filing for Q4 2015, filed 10 Feb 2016.